4.7 Review

Unraveling Vascular Inflammation From Immunology to Imaging

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 11, 页码 1403-1412

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.750

关键词

cardiovascular imaging; monocytes; neutrophils; T cells

资金

  1. Abbvie
  2. Janssen
  3. Novartis
  4. Regeneron
  5. Sanofi
  6. Celgene
  7. Pfizer
  8. Eli Lilly
  9. Navidea Pharmaceuticals
  10. KOWA Pharmaceuticals
  11. Gilead Sciences
  12. Theratechnologies
  13. National Heart, Lung, and Blood Institute
  14. AstraZenenca
  15. Kowa
  16. Actelion
  17. Genentech

向作者/读者索取更多资源

Inflammation is a critical factor in early atherosclerosis and its progression to myocardial infarction. The search for valid surrogate markers of arterial vascular inflammation led to the increasing use of positron emission tomography/computed tomography. Indeed, vascular inflammation is associated with future risk for myocardial infarction and can be modulated with short-term therapies, such as statins, that mitigate cardiovascular risk. However, to better understand vascular inflammation and its mechanisms, a panel was recently convened of world experts in immunology, human translational research, and positron emission tomographic vascular imaging. This contemporary review first strives to understand the diverse roles of immune cells implicated in atherogenesis. Next, the authors describe human chronic inflammatory disease models that can help elucidate the pathophysiology of vascular inflammation. Finally, the authors review positron emission tomography-based imaging techniques to characterize the vessel wall in vivo. (J Am Coll Cardiol 2017;70:1403-12) Published by Elsevier on behalf of the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据